Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
0.1521
0.00 (0.00%)
Tonix Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other serious medical conditions
The company is dedicated to advancing its pipeline of product candidates, which include treatments for conditions such as migraines, post-traumatic stress disorder, and various infectious diseases. By leveraging its expertise in drug development and utilizing strategic collaborations, Tonix aims to bring novel treatment options to market that address unmet medical needs and improve patient outcomes.
Tonix Pharmaceuticals (NASDAQTNXP) announced the promotion of Siobhan Fogarty to chief technical officer. Fogarty, who joined Tonix in 2016, previously served as executive vice president of product development and has over 25 years of experience in pharmaceutical and biotech product development, manufacturing and quality. Her promotion comes as the company prepares for the U.S. Food and Drug Administration’s Aug. 15, 2025, decision on TNX-102 SL, a non-opioid treatment for fibromyalgia. Fogarty’s expertise spans small molecules, biologics and live-virus vaccines, having held leadership roles at Elan Corporation, GlaxoSmithKline, Fuisz Technologies and Biovail Corporation.
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Tonix Pharmaceuticals (NASDAQTNXP) will implement a 1-for-100 reverse stock split, effective at market open on Feb. 5, 2025, to meet NASDAQ’s $1.00 minimum bid price requirement. The company’s stock will continue trading under the symbol “TNXP” with a new CUSIP number. The split applies to outstanding common shares, warrants, and stock options but does not reduce authorized shares. Fractional shares will be rounded up to the nearest whole share. VStock Transfer LLC will manage the exchange process for shareholders
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Tonix Pharmaceuticals (NASDAQTNXP) has appointed Gary Ainsworth as Vice President, Market Access, as the company prepares for the potential FDA approval of TNX-102 SL, a non-opioid analgesic for fibromyalgia, with a PDUFA decision date set for Aug. 15, 2025. Ainsworth brings extensive experience from roles at Eversana Intouch, Havas Gemini, Baxter International, Roche Laboratories, and Sanofi, where he developed market access strategies and payer-focused resources. His appointment strengthens Tonix’s commercial strategy to support the launch of TNX-102 SL, aimed at addressing the needs of fibromyalgia patients, a condition primarily affecting women.
Tonix Pharmaceuticals (NASDAQTNXP), a biopharmaceutical company focused on marketed products and development candidates, announced its participation in two investor conferences in January 2025. Seth Lederman, M.D., President and CEO, will present and join a panel discussion at the 8th Annual Neuroscience Innovation Forum on Jan. 12 at the Marines Memorial Club in San Francisco. He will also present at the 2025 Biotech Showcase on Jan. 14 at the Hilton San Francisco Union Square. Replays of the presentations will be available on Tonix’s website under the IR Events tab. Interested investors can arrange meetings through the respective conference coordinators.
